Has Han-Ting Lin, MD received payments from drug or device companies?

Yes. Drug and device makers reported $508 in general payments to Han-Ting Lin, MD across 9 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Han-Ting Lin, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Han-Ting Lin, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Han-Ting Lin, MD

Hematology & Oncology · Salem, NHNPI 1114019148

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by AstraZeneca at 59.0% of the total. Reporting peaked in 2019 at $300 and has fallen 85.8% since, to $43 in 2024.

$508in general payments, 2019–2025

Across 9 payments — averaging $56.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$300
E.r. Squibb & Sons, L.L.C.$154
Pfizer$42
Gilead$12

What the payments were for

Speaking & faculty fees$30059%
Food & beverage$10521%
Education$10320%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	2	$300
E.r. Squibb & Sons, L.L.C.	4	$154
Pfizer	2	$42
Gilead	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

SOLIRIS$300
OPDIVO$105

How this compares

$508 in reported general payments places this provider in the 65th percentile of 61 hematology & oncology providers in New Hampshire.

See all hematology & oncology providers in New Hampshire →

Medicare billing

Part B allowed, 2024

$1,197,225

Medicare patients

285

Services billed

55,475

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lenalidomide	48	$651,676
BrukinsaZanubrutinib	32	$468,675
RevlimidLenalidomide	20	$368,003
PomalystPomalidomide	15	$290,475
TasignaNilotinib Hcl	13	$244,907
JakafiRuxolitinib Phosphate	12	$211,918
KisqaliRibociclib Succinate	12	$178,785
DopteletAvatrombopag Maleate	11	$160,208
EliquisApixaban	45	$30,857
Abiraterone Acetate	21	$16,660
Fondaparinux Sodium	12	$6,338
Hydroxyurea	74	$1,579
Tramadol Hcl	19	$1,577
Letrozole	59	$1,333
Imatinib Mesylate	19	$1,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst	$154	$290,47515 claims
PfizerEliquis	$42	$30,85745 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 61 hematology & oncology providers in New Hampshire.

Other hematology & oncology in Salem

Frederick LansiganLebanon$23K
Parth ShahLebanon$18K
Nancy ChunNashua$7K
Amy BessnowDover$6K
Konstantin DragnevLebanon$5K
Keisuke ShiraiLebanon$5K
Eric LubinerNorth Conway$3K
David ReismanManchester$2K
Ivy Riano MonsalveLebanon$2K
Yoko FukudaPortsmouth$1K

See the full list for New Hampshire →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →